JP6106182B2 - Ｐａｒｐ−１阻害剤としての３−フェニル−イソキノリン−１（２ｈ）−オン誘導体 - Google Patents
Ｐａｒｐ−１阻害剤としての３−フェニル−イソキノリン−１（２ｈ）−オン誘導体 Download PDFInfo
- Publication number
- JP6106182B2 JP6106182B2 JP2014542801A JP2014542801A JP6106182B2 JP 6106182 B2 JP6106182 B2 JP 6106182B2 JP 2014542801 A JP2014542801 A JP 2014542801A JP 2014542801 A JP2014542801 A JP 2014542801A JP 6106182 B2 JP6106182 B2 JP 6106182B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- fluoro
- compound
- isoquinolin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C*)N(*)I Chemical compound CC(C*)N(*)I 0.000 description 1
- ZDPKQPFAGFYCIG-FMQUCBEESA-N Cc1cc(F)ccc1/C(/OCCN)=C(/c(cc1)cc2c1OCCO2)\NC=O Chemical compound Cc1cc(F)ccc1/C(/OCCN)=C(/c(cc1)cc2c1OCCO2)\NC=O ZDPKQPFAGFYCIG-FMQUCBEESA-N 0.000 description 1
- OOMGICXJISMCLR-UHFFFAOYSA-N NCCOC(c(cc1)c2c(F)c1F)=C(c(cc1)ccc1Br)NC2=O Chemical compound NCCOC(c(cc1)c2c(F)c1F)=C(c(cc1)ccc1Br)NC2=O OOMGICXJISMCLR-UHFFFAOYSA-N 0.000 description 1
- POAFYPSDLXGQBX-UHFFFAOYSA-N NCCOC(c(cc1)c2cc1F)=C(c(cc1)cc(Br)c1N1CCOCC1)NC2=O Chemical compound NCCOC(c(cc1)c2cc1F)=C(c(cc1)cc(Br)c1N1CCOCC1)NC2=O POAFYPSDLXGQBX-UHFFFAOYSA-N 0.000 description 1
- BFJMBXAFUUTYIR-UHFFFAOYSA-N NCCOC(c(cc1)c2cc1F)=C(c(cc1Cl)ccc1Cl)NC2=O Chemical compound NCCOC(c(cc1)c2cc1F)=C(c(cc1Cl)ccc1Cl)NC2=O BFJMBXAFUUTYIR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11190687 | 2011-11-25 | ||
| EP11190687.1 | 2011-11-25 | ||
| EP12161489 | 2012-03-27 | ||
| EP12161489.5 | 2012-03-27 | ||
| PCT/EP2012/073125 WO2013076090A1 (en) | 2011-11-25 | 2012-11-20 | 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014533709A JP2014533709A (ja) | 2014-12-15 |
| JP6106182B2 true JP6106182B2 (ja) | 2017-03-29 |
Family
ID=47227787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542801A Active JP6106182B2 (ja) | 2011-11-25 | 2012-11-20 | Ｐａｒｐ−１阻害剤としての３−フェニル−イソキノリン−１（２ｈ）−オン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9422243B2 (enExample) |
| EP (1) | EP2788328B1 (enExample) |
| JP (1) | JP6106182B2 (enExample) |
| KR (1) | KR20140097457A (enExample) |
| CN (1) | CN103946214B (enExample) |
| AU (1) | AU2012342562B2 (enExample) |
| BR (1) | BR112014012031A2 (enExample) |
| CA (1) | CA2856759A1 (enExample) |
| CL (1) | CL2014001323A1 (enExample) |
| EA (1) | EA027800B1 (enExample) |
| ES (1) | ES2676068T3 (enExample) |
| IN (1) | IN2014CN04671A (enExample) |
| MX (1) | MX2014006015A (enExample) |
| WO (1) | WO2013076090A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2822656B1 (en) | 2012-03-07 | 2016-10-19 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| US9611223B2 (en) | 2013-09-11 | 2017-04-04 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| JP6663350B2 (ja) * | 2014-01-16 | 2020-03-11 | クロヴィス・オンコロジー，インコーポレーテッド | ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用 |
| TN2018000130A1 (en) | 2015-11-06 | 2019-10-04 | Neurocrine Biosciences Inc | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
| WO2021113478A1 (en) | 2019-12-06 | 2021-06-10 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| AU2023290506A1 (en) | 2022-06-15 | 2025-01-23 | Astrazeneca Ab | Combination therapy for treating cancer |
| AU2024268579A1 (en) | 2023-05-11 | 2026-01-15 | Astrazeneca Ab | Combination of a parp1 inhibitor and a selective estrogen degrader for treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1397350B1 (en) | 2001-05-08 | 2007-02-28 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
| US20040176361A1 (en) | 2001-05-23 | 2004-09-09 | Masakazu Fujio | Fused heterocyclic compound and medicinal use thereof |
| WO2004009556A1 (ja) | 2002-07-24 | 2004-01-29 | Kyorin Pharmaceutical Co., Ltd. | ４−置換アリール−５−ヒドロキシイソキノリノン誘導体 |
| JP5411152B2 (ja) * | 2008-02-22 | 2014-02-12 | Ｍｓｄ株式会社 | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| TWI499418B (zh) * | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
-
2012
- 2012-11-20 MX MX2014006015A patent/MX2014006015A/es unknown
- 2012-11-20 KR KR1020147017409A patent/KR20140097457A/ko not_active Withdrawn
- 2012-11-20 US US14/358,537 patent/US9422243B2/en active Active
- 2012-11-20 BR BR112014012031A patent/BR112014012031A2/pt not_active IP Right Cessation
- 2012-11-20 AU AU2012342562A patent/AU2012342562B2/en not_active Ceased
- 2012-11-20 WO PCT/EP2012/073125 patent/WO2013076090A1/en not_active Ceased
- 2012-11-20 IN IN4671CHN2014 patent/IN2014CN04671A/en unknown
- 2012-11-20 JP JP2014542801A patent/JP6106182B2/ja active Active
- 2012-11-20 CA CA2856759A patent/CA2856759A1/en not_active Abandoned
- 2012-11-20 ES ES12791464.6T patent/ES2676068T3/es active Active
- 2012-11-20 CN CN201280057586.4A patent/CN103946214B/zh active Active
- 2012-11-20 EA EA201491026A patent/EA027800B1/ru not_active IP Right Cessation
- 2012-11-20 EP EP12791464.6A patent/EP2788328B1/en active Active
-
2014
- 2014-05-20 CL CL2014001323A patent/CL2014001323A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014006015A (es) | 2014-06-04 |
| US20140336192A1 (en) | 2014-11-13 |
| CL2014001323A1 (es) | 2014-09-05 |
| AU2012342562B2 (en) | 2017-02-23 |
| WO2013076090A1 (en) | 2013-05-30 |
| EP2788328B1 (en) | 2018-01-31 |
| EP2788328A1 (en) | 2014-10-15 |
| HK1200166A1 (en) | 2015-07-31 |
| AU2012342562A1 (en) | 2014-07-10 |
| BR112014012031A2 (pt) | 2017-05-30 |
| EA201491026A1 (ru) | 2014-11-28 |
| IN2014CN04671A (enExample) | 2015-09-18 |
| US9422243B2 (en) | 2016-08-23 |
| ES2676068T3 (es) | 2018-07-16 |
| CN103946214A (zh) | 2014-07-23 |
| CN103946214B (zh) | 2016-08-17 |
| JP2014533709A (ja) | 2014-12-15 |
| EA027800B1 (ru) | 2017-09-29 |
| KR20140097457A (ko) | 2014-08-06 |
| CA2856759A1 (en) | 2013-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5731486B2 (ja) | Ｐａｒｐ−１阻害剤としてのイソキノリン−１（２ｈ）−オン誘導体 | |
| EP2454236B1 (en) | 3-oxo-2,3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors | |
| JP6106182B2 (ja) | Ｐａｒｐ−１阻害剤としての３−フェニル−イソキノリン−１（２ｈ）−オン誘導体 | |
| EP2454237B1 (en) | 3-oxo-2,3,-dihydro-1h-isoindole-4-carboxamides with selective parp-1 inhibition | |
| EP2736896B1 (en) | 3-oxo-2,3-dihydro-1h-indazole-4-carboxamide derivatives as parp-1 inhibitors | |
| HK1200166B (en) | 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors | |
| HK1166076B (en) | Isoquinolin-1 (2h) - one derivatives as parp-1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140724 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151119 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160623 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160927 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170214 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170303 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6106182 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |